Table 2 Clinical demographics of localized pancreatic cancer patients.
From: Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis
Characteristics | Surgery: 67 (100%) | No surgery: 14 (100%) |
|---|---|---|
Median age (range) | 70 (45–90) | 70 (40–90) |
Sex male/female | 31 (46%)/36 (54%) | 7 (50%)/ 7 (50%) |
Stage I/II | 25 (38%)/42 (62%) | 7 (50%)/ 7 (50%) |
Borderline resectable (y/n) | 17 (25%)/50 (75%) | 10 (71%)/4 (29%) |
CA19-9 > 37 U/mL (y/n) | 36 (54%)/31 (46%) | 9 (64%)/5 (36%) |
Neoadjuvant treatment intent (y/n) | 26 (39%)/41 (61%) | 8 (57%)/6 (43%) |
Positive lymph nodes (y/n) | 33 (49%)/34 (51%) | 3 (21%)/11 (79%) |
